Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2020-01-12 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
上海市锦天城律师事务所关于公司首次公开发行股票申请在深圳证券交易所创业板上市的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by Shanghai Jintiancheng Law Firm regarding Zhejiang Tailin Biotechnology Co., Ltd.'s initial public offering (IPO) application for listing on the Shenzhen Stock Exchange's ChiNext board. It references relevant Chinese securities laws, company approvals, regulatory approvals from the China Securities Regulatory Commission (CSRC), and compliance with listing rules. The document is a formal legal opinion supporting the IPO process, not a financial report, earnings release, or management discussion. It is not a proxy statement, voting result, or board change announcement. It is a specialized legal opinion letter related to the IPO process, which does not fit into categories like Annual Report, Interim Report, or Capital/Financing Update. The closest fitting category is Regulatory Filings (RNS), as it is a regulatory compliance document that does not fit other specific categories. The document length (9665 characters) and content confirm it is not a brief announcement or a report publication announcement. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2020-01-12 Chinese
安信证券股份有限公司关于公司首次公开发行股票并在创业板上市之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is a detailed listing sponsorship letter (上市保荐书) from Anxin Securities for Zhejiang Tailin Biotechnology Co., Ltd. regarding its initial public offering (IPO) and listing on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It includes company background, financial data for recent years, share issuance details, shareholder lock-up commitments, and the sponsor's confirmation of compliance with relevant laws and regulations. The document is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a formal sponsorship document related to the IPO process, which fits the category of Capital/Financing Update (CAP) as it pertains to the company's fundraising and capital structure changes through the IPO.
2020-01-12 Chinese
首次公开发行股票并在创业板上市之上市公告书
Regulatory Filings Classification · 95% confidence The document is titled as a "上市公告书" which translates to "Listing Announcement" or "IPO Listing Announcement" for Zhejiang Tailin Bioengineering Co., Ltd. It contains detailed commitments and disclosures related to the company's initial public offering (IPO) and listing on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). The content includes shareholder lock-up commitments, share repurchase commitments, investor protection measures, dividend policies, and stock price stabilization plans. It is not a financial report like an annual or interim report, nor is it a transcript, audit report, or earnings release. It is a formal announcement related to the company's IPO and listing event, which fits best under the category of Regulatory Filings (RNS) as it is a regulatory disclosure document that does not fit other specific categories. The document length is substantial and contains detailed regulatory disclosures, not just a brief announcement or a report publication notice. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-01-12 Chinese
首次公开发行股票并在创业板上市之上市公告书提示性公告
Regulatory Filings Classification · 95% confidence The document is a listing announcement for Zhejiang Tailin Biotechnology Co., Ltd. regarding its initial public offering (IPO) and listing on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It includes details such as stock code, total shares after IPO, and risk warnings. The document is relatively short (1364 characters) and primarily serves as an official announcement of the listing event rather than a detailed financial report or prospectus. It references where the full prospectus and listing documents can be found but does not contain substantive financial data or detailed report content itself. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about the IPO listing event and does not meet criteria for other specific categories like Capital/Financing Update or Prospectus.
2020-01-12 Chinese
首次公开发行股票并在创业板上市网上定价发行结果公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the results of an initial public offering (IPO) of shares by Zhejiang Tailin Biotechnology Co., Ltd. It details the pricing, subscription, and allocation results of the stock issuance. The text includes information about the underwriting, subscription numbers, amounts, and the final allotment. It does not contain financial statements or detailed financial performance data, nor is it a full report. It is a capital market update specifically about the issuance and pricing of new shares. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short (1371 characters), consistent with an announcement rather than a full report.
2020-01-08 Chinese
首次公开发行股票并在创业板上市网上定价发行摇号中签结果公告
Capital/Financing Update Classification · 95% confidence The document is an announcement of the lottery results for the online pricing issuance of shares for Zhejiang Tailin Biotechnology Co., Ltd. It details the winning numbers for the stock subscription lottery related to the company's initial public offering (IPO) on the Growth Enterprise Market. The document includes instructions for investors on how to check their lottery results and payment obligations. It does not contain financial statements, management discussion, or detailed financial data. The document length is short (1613 characters) and it is clearly an announcement of lottery results related to a capital issuance event. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as IPOs and share issuances.
2020-01-06 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.